SCHEMBL1633965

SCHEMBL1633965

CC1(C)CC(C)(C)CC2(CC2C(N)=O)C1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.33
APLNR P35414 1/20 0.33
PKM P14618 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1636281 0.80 APLNR (0.44) APLNRKMT2A
SCHEMBL1634827 0.75 GAA (0.32) GAA
SCHEMBL20985234 0.74
SCHEMBL19567867 0.74
SCHEMBL20985222 0.74
SCHEMBL13592131 0.71 APLNR (0.34) GAAAPLNRPKMKMT2A
SCHEMBL29567674 0.71 TSHR (0.36) GAAPKM
SCHEMBL238946 0.71
SCHEMBL938236 0.71
SCHEMBL8596049 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US claimed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP claimed
EP-1558230-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2005-08-03 EP claimed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US claimed
WO-2004037240-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2004-05-06 WO claimed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US claimed
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US disclosed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP disclosed
EP-1558230-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2005-08-03 EP disclosed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US disclosed
WO-2004037240-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2004-05-06 WO disclosed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A GAA 1897/4885APLNR 2206/4885PKM 1286/4885
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A GAA 1897/4885APLNR 2206/4885PKM 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.